XIFAXAN® (rifaximin) 550 mg tablets, for the upcoming round of drug price negotiations. According to InvestingPro analysis, the company currently trades below its Fair Value, suggesting potential ...

has selected XIFAXAN ® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of ...

Rifaximin is a semi-synthetic derivative of rifampin and acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase blocking one of the steps in transcription. This results in ...

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.

Amneal Pharmaceuticals (AMRX) announced that the FDA has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which ...

Bausch Health (BHC) Companies and Salix Pharmaceuticals acknowledged that the Centers for Medicare and Medicaid Services has selected XIFAXAN 550 mg tablets as one of the medicines for the second ...